No specific therapy is approved yet for childhood interstitial lung disease (chILD).

Improved understanding of disease pathogenesis is instrumental to the development of novel therapies.

The disease course is highly heterogeneous, and when treatment is required, immunosuppressive and anti-inflammatory drugs are often the first-line therapies.

Multi-stakeholder collaboration is key to develop novel drugs and move the field of chILD forward.